A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053).
D000380:Agranulocytosis / Q000139:chemically induced; D000818:Animals; D001682:Biological Availability; D001943:Breast Neoplasms / Q000188:drug therapy; D003609:Dactinomycin / Q000008:administration & dosage* / Q000097:blood / Q000633:toxicity; D004285:Dogs; D006207:Half-Life; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000188:drug therapy
D003609:Dactinomycin